Table 2. Cytotoxic Effect of... | American Society of Hematology

Table 2.

Cytotoxic Effect of Fludarabine, Mafosfamide, and Mitoxantrone on B-CLL Lymphocytes

Patient No.	Viability (%)
Patient No.	Control	Fludarabine	Mitoxantrone	Mafosfamide	M + Mf	F + Mf	F + M	F + M + Mf
1	80 ± 4	46 ± 3	57 ± 1	71 ± 2	46 ± 2	20 ± 3	18 ± 2	11 ± 2
2	92 ± 6	71 ± 3	80 ± 7	87 ± 3	75 ± 0.8	39 ± 1	51 ± 1	33 ± 2
3	100 ± 6	83 ± 0.6	88 ± 1	94 ± 1	82 ± 4	30 ± 0.5	42 ± 5	21 ± 1
4	91 ± 3	67 ± 2	87 ± 8	90 ± 5	65 ± 2	43 ± 0.9	57 ± 6	36 ± 3
5	59 ± 8	29 ± 0.3	17 ± 1	38 ± 6	16 ± 0.2	11 ± 1	11 ± 0.1	9 ± 0.1
6	79 ± 2	66 ± 3	65 ± 4	79 ± 2	67 ± 1	51 ± 2	50 ± 4	43 ± 2
7	75 ± 2	57 ± 5	56 ± 3	76 ± 3	56 ± 3	31 ± 0.9	37 ± 4	24 ± 0.8
8	82 ± 2	50 ± 1	69 ± 5	76 ± 4	64 ± 0.5	38 ± 2	38 ± 0.6	31 ± 1
9	81 ± 3	69 ± 3	62 ± 0.2	77 ± 2	58 ± 6	47 ± 2	44 ± 2	35 ± 3
10	100 ± 5	81 ± 10	37 ± 4	100 ± 3	34 ± 2	35 ± 1	22 ± 3	16 ± 2
11	93 ± 2	64 ± 2	87 ± 0	69 ± 1	60 ± 3	30 ± 1	60 ± 1	27 ± 1
12	96 ± 13	60 ± 6	56 ± 9	74 ± 7	38 ± 2	10 ± 2	18 ± 4	8 ± 0.4
13	71 ± 18	31 ± 5	35 ± 4	68 ± 4	27 ± 3	10 ± 3	13 ± 3	7 ± 2
14	69 ± 13	27 ± 6	33 ± 5	42 ± 3	29 ± 2	19 ± 2	20 ± 2	16 ± 1
15	48 ± 1	16 ± 0.5	17 ± 0.5	34 ± 1	16 ± 1	14 ± 1	11 ± 1	13 ± 1
16	94 ± 3	72 ± 1	96 ± 2	86 ± 2	85 ± 6	46 ± 5	61 ± 2	46 ± 0.4
17	100 ± 0.4	81 ± 6	90 ± 1	91 ± 6	80 ± 0.2	35 ± 1	56 ± 10	28 ± 1
18	73 ± 3	45 ± 1	62 ± 6	55 ± 2	49 ± 1	16 ± 1	33 ± 5	16 ± 4
19	99 ± 2	53 ± 8	65 ± 2	80 ± 4	56 ± 4	28 ± 2	34 ± 3	26 ± 2
20	68 ± 4	53 ± 7	61 ± 4	64 ± 2	50 ± 1	40 ± 2	41 ± 1	37 ± 1

Mean ± SD	82 ± 16	56 ± 19^*	62 ± 23^*	73 ± 19^*	53 ± 21	29 ± 13^†,^‡	36 ± 17^†	24 ± 12^2-153

Patient No.	Viability (%)
Patient No.	Control	Fludarabine	Mitoxantrone	Mafosfamide	M + Mf	F + Mf	F + M	F + M + Mf
1	80 ± 4	46 ± 3	57 ± 1	71 ± 2	46 ± 2	20 ± 3	18 ± 2	11 ± 2
2	92 ± 6	71 ± 3	80 ± 7	87 ± 3	75 ± 0.8	39 ± 1	51 ± 1	33 ± 2
3	100 ± 6	83 ± 0.6	88 ± 1	94 ± 1	82 ± 4	30 ± 0.5	42 ± 5	21 ± 1
4	91 ± 3	67 ± 2	87 ± 8	90 ± 5	65 ± 2	43 ± 0.9	57 ± 6	36 ± 3
5	59 ± 8	29 ± 0.3	17 ± 1	38 ± 6	16 ± 0.2	11 ± 1	11 ± 0.1	9 ± 0.1
6	79 ± 2	66 ± 3	65 ± 4	79 ± 2	67 ± 1	51 ± 2	50 ± 4	43 ± 2
7	75 ± 2	57 ± 5	56 ± 3	76 ± 3	56 ± 3	31 ± 0.9	37 ± 4	24 ± 0.8
8	82 ± 2	50 ± 1	69 ± 5	76 ± 4	64 ± 0.5	38 ± 2	38 ± 0.6	31 ± 1
9	81 ± 3	69 ± 3	62 ± 0.2	77 ± 2	58 ± 6	47 ± 2	44 ± 2	35 ± 3
10	100 ± 5	81 ± 10	37 ± 4	100 ± 3	34 ± 2	35 ± 1	22 ± 3	16 ± 2
11	93 ± 2	64 ± 2	87 ± 0	69 ± 1	60 ± 3	30 ± 1	60 ± 1	27 ± 1
12	96 ± 13	60 ± 6	56 ± 9	74 ± 7	38 ± 2	10 ± 2	18 ± 4	8 ± 0.4
13	71 ± 18	31 ± 5	35 ± 4	68 ± 4	27 ± 3	10 ± 3	13 ± 3	7 ± 2
14	69 ± 13	27 ± 6	33 ± 5	42 ± 3	29 ± 2	19 ± 2	20 ± 2	16 ± 1
15	48 ± 1	16 ± 0.5	17 ± 0.5	34 ± 1	16 ± 1	14 ± 1	11 ± 1	13 ± 1
16	94 ± 3	72 ± 1	96 ± 2	86 ± 2	85 ± 6	46 ± 5	61 ± 2	46 ± 0.4
17	100 ± 0.4	81 ± 6	90 ± 1	91 ± 6	80 ± 0.2	35 ± 1	56 ± 10	28 ± 1
18	73 ± 3	45 ± 1	62 ± 6	55 ± 2	49 ± 1	16 ± 1	33 ± 5	16 ± 4
19	99 ± 2	53 ± 8	65 ± 2	80 ± 4	56 ± 4	28 ± 2	34 ± 3	26 ± 2
20	68 ± 4	53 ± 7	61 ± 4	64 ± 2	50 ± 1	40 ± 2	41 ± 1	37 ± 1

Mean ± SD	82 ± 16	56 ± 19^*	62 ± 23^*	73 ± 19^*	53 ± 21	29 ± 13^†,^‡	36 ± 17^†	24 ± 12^2-153

B-CLL lymphocytes were incubated at 37°C for 48 hours in the absence of any factor (control), with mitoxantrone (M; 0.5 μg/mL), with fludarabine (F; 1 μg/mL), with mafosfamide (Mf; 1 μg/mL), or with the combinations of these drugs. Cell viability was determined by the MTT assay as described in Materials and Methods and is expressed as the percentage with respect to the viability of control cells at the beginning of the culture. Data are shown as the mean value ± SD of triplicate cultures.

P < .01 v control.

†

P < .01 v fludarabine.

‡

P = .172 v fludarabine + mitoxantrone.

F2-153

P = .08 v fludarabine + mafosfamide.

View Large

This Feature Is Available To Subscribers Only